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Summary 
The  minimum  structural  requirements  for  peptide  interactions  with  major  histocompatibility 
complex  (MHC)  class  II  molecules  and  with  T  cell  receptors  (TCKs)  were  examined.  In  this 
report  we  show  that  substituting  alanines  at  all  but  five  amino  acids  in  the  myelin  basic  protein 
(MBP)  peptide  Ac1-11  does  not  alter  its  ability  to  bind  Act"A/3"  (MHC  class  II  molecules),  to 
stimulate  specific  T  cells  and,  surprisingly,  to  induce  experimental  autoimmune  encephalomyelitis 
(EAE)  in  (PL/J  x  SJL/J)F1  mice.  Most  other  amino  acid  side  chains  in  the  Ac1-11  peptide  are 
essentially  irrelevant  for  T  cell  stimulation  and  for  disease  induction.  Further  analysis  revealed 
that  binding  to  Aoz"A/~  occurred  with  a  peptide  that  consists  mainly  of  ahnines  and  only  three 
of  the  original  residues  of  Ac1-11.  Moreover,  when  used  as  a  coimmunogen  with  MBP  Acl-ll, 
this  peptide  inhibited  EAE.  The  finding  that  a  specific  in  vivo  response  can  be  generated  by 
a  peptide  containing  only  five  native  residues  provides  evidence  that  disease-inducing  TCRs  recognize 
only  a  very  short  sequence  of  the  MHC-bound  peptide. 
S 
Pecific  interactions  between  TCRs  and  peptides  bound  to 
MHC  molecules  are  crucial  for  T  call  stimulation  (1). 
Class  II  molecules  of  the  MHC  bind  peptides  and  present 
them  to  CD4*  Th  cells  (1,  2).  Much  of  our  understanding 
of  peptide  MHC  interactions  and  their  subsequent  recogni- 
tion  by  specific  T  calls  has  rdied  on  the  use  of  single  amino 
add  substitutions  in  peptides  to  identify  key  amino  acids  re- 
quired  for  binding  to  various  MHC molecules  and  for 
stimulating  antigen-spedfic  T  cells  in  vitro  (3-7).  To  date, 
there  is  no  evidence  that  antigen-specific  in  vitro  and  in  vivo 
responses  can  be  initiated  by  a  peptide  containing  only  a  few 
principal  MHC  and  TCR  contact  residues.  To  determine  the 
minimum  MHC  class  II  binding  and  T  cell  recognition  re- 
quirements  for  peptide,  we  studied  presentation  of  the  im- 
munodominant  N-terminal  myelin  basic  protein  (MBP)  pep- 
tide  Ac1-11,  which  induces  experimental  autoimmune 
encephalomyelitis  (EAE)  in  (PL/J  x SJL/J)F1  mice  (8). 
EAE  is  an  inflammatory  and  demyelinating  disease  of  the  cen- 
tral  nervous  system  that  serves  as  a  model  for  the  human  dis- 
ease  multiple  sclerosis.  Responses  to  Ac1-11  are  restricted  by 
Ace"A/3  u  (MHC  dass  II)  (5,  8).  Critical  amino  acids  in  Acl- 
11  have  been  identified  for  binding  to  Ao~"A/~"  and  for  rec- 
ognition  by  the  TCR  (see  brow)  (3,  4).  Using  peptide  analogs 
of  Acl-ll  consisting  mainly  of  alanines,  we  have  examined 
the  minimum  residues  in  Ac1-11  for  establishing  specific 
binding  to  Ac~"A/3  ~,  for  stimulation  of  specific  T  cells  in 
vitro,  and,  more  importantly,  for  inducing  EAE.  The  data 
presented  in  this  report  imply  that  the  overall  conformation 
of  the  whole  peptide  (bound  to  MHC  class  II  molecules) 
may  not  be  crucial  for  T  cell  recognition  in  vitro  and  in  vivo. 
Materials and Methods 
Ani~k  PL/J and (PL/J x  S3L/J)FI  mice were purchased 
from The Jackson  Laboratory  (Bar  Harbor,  ME). 
Peptide  Anagem. Peptides  were synthesized  by standard  Fmoc 
chemistry,  purified  if necessary  (90-99% pure),  and structure 
confirmed  by amino acid  analysis  and mass spectroscopy.  Pepddc 
Ac3.5  does  not  dissolve  in  PBS especially  at  higher  concentrations. 
OVA 323-339 was biotinylated  by a  short  chain  NHS-biotin (N- 
hydroxy-succinimidebiotin)  from  Pierce  Chemical  Co. (Rockford, 
IL),  as  described  (9).  All  amino  acids  are  indicated  in  single  letter 
codes. 
Hybridoma  Assay.  The  T  cell  hybridoma  1934.4  was  established 
from  the  T  cell  done  PJR-25  (3).  Activation  of  1934.4  ceUs  was 
assessed  by  measuring  Ib2  production  as  described  previously  (3). 
In  experiments  where  competition  for  antigen  presentation  was 
examined,  competitor  peptides  were  coincubated  with  Ac1-11, 
APCs,  and  1934.4  for  24  h.  Supernatants  were  harvested  and  as- 
sayed  for  IL-2  as  above. 
AaeA#'  Transfectants.  Ac~"AB"  transfectants,  in  which  the 
class  II  negative  cell  line  M12.C3  (10)  was  used  as  a  recipient,  were 
prepared  as  described  (9).  One  cell  line  expressing  Acx"  and  A~" 
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View,  CA)  by  selecting  the  top  5%  brightest  cells  and  plating  one 
cell  per  well.  Clone  622.18  was  selected  and  used  in  this  study. 
Cell-suCace  Peptide  Binding  Assay.  A  total  of  105  cells  (622.18), 
expressing  Ac~Afl  ~  were  incubated  either  alone  with  biotinylated 
OVA  323-339  peptide  (10  #M),  or  with  competitor  peptides  (400 
/zM)  and  biotinylated  OVA  323-339  (10  #M)  together  for  18-20  h. 
After  washing,  cells  were  incubated  (30  rain  at  4°C)  with  strep- 
tavidin  Texas  red  (Pierce  Chemical  Co.)  (1  rag/100  ml  cell  suspen- 
sion),  and  analyzed  by  flow  cytometry  (9).  To  measure  the  relative 
amount  of  streptavidin  Texas  red  bound,  the  mean  fluorescence  was 
determined  for  at  least  5,000  propidium  iodide  negative  cells.  The 
background,  measured  in  the  absence  of  biotinylated  peptide,  was 
subtracted  from  each  signal.  Specific  binding  is  expressed  as  per- 
cent  inhibition  of  the  control  binding  ofbiotinylated  OVA  323-339 
in  the  absence  of  competitors  using  the  following  formula: 
F  /  Signal  with  \  7 
percent  /  (competitors_background~ 
J 
inhibition  =  100-  1~  Signal  without]  ×  100 
L  \competitors-background/ 
Induction  of  EAE. EAE  was  induced  by  injecting  MBP  Ac1-11 
emulsified  in  CFA  subcutaneously  at  the  base  of  the  tail  in  a  total 
volume  of  0.1  ml.  For  coimmunization,  the  inhibitor  peptides  were 
mixed  in  the  same  emulsion.  200  ng  of  pertussis  toxin  (JR.H  Bio- 
sciences,  Woodland,  CA)  was  injected  intravenously  at  the  time  of 
immunization  and  again  2  d  later.  Mice  were  examined  daily  as 
described  previously  (3)  and  in  figure  legends. 
Results 
Peptide  Containing  only  the  Key  MHC and  TCR Residues 
Stimulate  Acl-ll-specific  T  Cells  In  Vitro.  Peptide  analogs  of 
Ac1-11  with  multiple  alanine  substitutions  were  synthesized 
(Fig.  1  A).  When  the  peptides  were  analyzed  for  stimulation 
of  the  Ac1-ll-specific  and  ActuArY-restricted  T cell  hy- 
bridoma  1934.4,  surprisingly  few  of  the  native  amino  acids 
were  required  (Fig.  1  B).  The  substituted  peptides  Ac3.5.6.10 
and  Ac3.5.6  stimulated  1934.4  better,  and  Ac3.4.5.6  stimu- 
lated  less  than  wild  type  Ac1-11.  All  other  peptides  failed  to 
stimulate  the  hybridoma  1934.4  (Fig.  1  B).  The  enhanced 
T  cell  stimulation  by  Ac3.5.6  and  Ac3.5.6.10  is  probably  due 
to  alanine  at  position  four,  which  we  know  increases  binding 
to  Aa~Afl  ~  (3,  4).  These  results  demonstrate  that  only  a 
minimum  of  four  native  amino  acids  (at  positions  1,  3,  5, 
and  6)  in  Ac1-11  are  required  to  establish  sufficient  contact 
with  the  MHC  class  II  and  the  TCR  to  stimulate  Acl- 
11-specific  T  cells  in  vitro  (see  peptide  Ac3.5.6).  However, 
recognition  by  the  TCR  of  a  critical  residue  appears  to  be 
very  specific  since  a  conservative  change  at  position  3  (gluta- 
mine  to  asparagine)  in  both  Ac1-11  and  Ac3.5.6  abrogates 
recognition  of  these  peptides,  although  these  peptides  still 
bind  to  Aot~Afl  u  (data  not  shown). 
To  determine  the  minimum  number  of  residues  in  Ac1-11 
that  bind  Ac~Afl  ~,  the  I-A  negative  cell  line  M12.C3  trans- 
fected  with  Aot~Afl  ~  genes  was  used  in  a  cell-surface  binding 
assay  (9,  and  see  legend  for  Fig.  1  C).  Binding  of  the  wild 
type  and  substituted  Ac1-11  peptides  was  assessed  by  compe- 
tition  with  the  biotinylated  (OVA)  peptide  323-339  by  flow 
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Figure  1.  T  cell  responses  to  alanine  analogs  of  Ac1-11.  (A)  Peptide 
analogs  of  Ac1-11.  (Tbp)  Sequence  of  Ac1-11  (single  letter  amino  acid  codes). 
(-)  Alanine  in  place  of  the  original  residues.  (Underlined)  Residues  in  ala- 
nine  peptides  represent  original  amino  acids.  (B)  Stimulation  of  an  Acl- 
11-specific  hybridoma  1934.4  by  Acl-ll  and  alanine-substituted  peptides. 
A  total  of  2  ×  104  T  cell  hybridoma  1934.4  cells,  peptides  (0.3-20  #M), 
and  2.5  x  10  s  spleen  cells  from  PL/J  mice  as  APCs  were  incubated  for 
18-20  h.  Culture  supernatants  were  analyzed  for  IL-2  using  the  HT-2  cell 
line  as  described  in  Materials  and  Methods.  (C)  Cell  surface  binding  assay. 
Ac~uA~  expressing  cells  (622.18)  were  incubated  with  10/zM  biotinylated 
OVA  323-339  either  alone  or  with  competitor  peptides  (400/zM)  as  in 
Materials  and  Methods.  Inhibition  of  biotinylated  OVA  323-339  binding 
to  cell  surface  AotuAfl  u  on  a  B  cell  transfectant  by  competitor  peptides 
is  shown  (see  Materials  and  Methods).  Background  for  this  experiment 
was  1.695,  and  signal  with  biotinylated  OVA  323-339  was  8.643.  Experi- 
ments  were  repeated  at  least  three  times  with  a  similar  pattern  of  inhibi- 
tion  of  binding  by  competitor  peptides. 
cytometry  (9).  Binding  of  OVA  323-339  is  specific,  as  only 
cell  lines  expressing  AcruAfl  u  and  AotdAfl  a  bind  the  peptide, 
but  cell  lines  expressing  AotkAB  k  or  no  class  II  do  not  (9). 
When  used  as  competitors  in  this  binding  assay,  the  alanine- 
substituted  peptides  (Fig.  1  A)  Ac3.5.6,  Ac3.5.6.10,  Ac3.5 
(this  peptide  is  poorly  soluble  in  culture  medium  and  PBS), 
and  AcS.6  efficiently  competed  for  the  cell-surface  binding 
ofbiotinylated  OVA  323-339.  On  the  other  hand,  Ac3.4.5.6, 
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(Ac1-11 has been shown to be a poor binder to AoL~A~ [3]). 
These results indicate that the positively charged argenine 
at position 5 in Ac1-11 is important in binding to Ao~"AB", 
presumably interacting with a negatively charged residue in 
the  MHC  molecule.  As  controls,  Acl-ll[4A]  and  OVA 
323-339,  which  are  known  to  bind  Aol"A/3  ",  inhibited 
binding of biotinylated OVA 323-339, but MBP89-101,  a 
nonbinder, did not (Fig.  1 C). For the most part, binding 
of these alanine analogs correlated well with T cell stimula- 
tion in vitro. However, peptides Ac5.6 and Ac3.5, which failed 
to  stimulate  specific T  cells,  showed  strong binding  to 
Ao~"AB  ~ in the cell-surface binding assay. Further evidence 
that peptides Ac5.6 and Ac3.5 bind to Aol~A~ is shown by 
a functional competition assay in which these peptides com- 
pete with Ac1-11 for antigen presentation to T cells (Fig. 2). 
Therefore, inability ofpeptides Ac5.6 and Ac3.5 to stimulate 
T cells appears to be due to absence of the T cell recognition 
residue glutamine at position 3 in Ac5.6 and proline at posi- 
tion 6 in Ac3.5. Both glutamine and proline have previously 
been shown to be important for T cell recognition of Ac1-11 
(3,  4). 
Polyalanine Peptides with Key MHC and TCR Residues In- 
duce EAE.  The minimum length required for various pep- 
tides (including Ac1-11) to induce in vivo responses has been 
determined (5-7). However, how many amino acids in these 
peptides (self or nonsdf) are directly involved in initiating 
immune responses is not known. This may have direct im- 
plications for the induction of autoimmune diseases since self 
peptides (with only a few crucial recognition residues in the 
peptide) may be presented by susceptibility MHC class II mol- 
ecules and recognized by pathogenic T cells. If a similar se- 
quence containing these critical residues is found in a nonself 
protein (e.g., viral), this sequence then might trigger the onset 
of autoimmunity through molecular mimicry (11, 12). To 
examine this issue, we were particalarly interested in deter- 
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Table  1.  Induction of EAE by Alanine-substituted Peptides 
Percent  Mean clinical  Day of 
Groups  incidence  scores  onset 
Ac1-11  87  (27/31)  3.8  12,4 
Ac3.4.5.6  80 (20/25)*  3.05  14 
Ac3.5.6.10  15.7 (3/18)  0.51  15.75 
Ac3.5.6  0  0  0 
EAE in (PL/J  x  SJL)F1 mice was induced as described in Materials and 
Methods. 100 nmol of peptides emulsified in CFA with 400/~g Microbac- 
tin'urn tuberculosis was injected subcutaneously at the base of the tail in 
a total volume of 100/,1 for each peptide.  Mice were examined daily 
for 30-35 d and were graded as follows: 1, limp tail; 2, partial hind limb 
paralysis;  3,  complete  hind limb paralysis; 4,  total paralysis;  and 5, 
moribund. 
* Chi-Square  =  0.013,  P  =  0.7 when compared with Ac1-11 group. 
mining whether peptides with multiple alanines could ini- 
tiate  responses  in  vivo.  Since  Ac3.5.6.10,  Ac3.5.6,  and 
Ac3.4.5.6 stimulated the T cell hybridoma 1934.4 (Fig. 1 B), 
they were used to induce EAE in (PL/J  x  SJL/J)F1 mice. 
Data summarized from three separate experiments are shown 
(Table 1). Only peptide Ac3.4.5.6 was able to induce EAE 
with a similar incidence and severity as Ac1-11. Thus, we have 
shown that most other side chains are not necessary for specific 
functions such as MHC class II binding, T  cell activation, 
and for EAE induction. 
Nonstimulatory Polyalanine Peptide Inhibits EAE.  Finally 
we examined whether the AoluAB%inding nonstimulatory 
alanine-substituted peptides (Ac5.6 and Ac3.5) could modu- 
late EAE.  Such modulation would indicate that these pep- 
tides may compete for MHC class II binding in vivo. Various 
studies have suggested that in vivo T cell responses, including 
EAE, can be inhibited by peptides that bind to MHC class 
II molecules (3, 9, 13-17). Since peptide Ac5.6 contains the 
minimum required amino acids for binding to AoeuAB  u (Fig. 
1 C) and also competes well with Ac1-11 for presentation 
in vitro (Fig. 2), we asked whether it would inhibit EAE. 
Table  2.  Inhibition  of EAE by Ac5.6 
Percent  Mean clinical  Day of 
Groups  incidence  scores  onset 
Ac1-11  92 (25/27)  3.4  12.75 
Ac1-11 + Ac5.6  40 (10/25)*  1.2  14.3 
Ac1-11 + Ac3.6  100 (18/18)  3.5  13.3 
Figur. 2.  Competition for antigen presentation between Ac1-11 and 
nonstimulatory  alanine-substituted peptides. Antigen presentation assays 
were performed as described in Fig. 1 B. Ac1-11 (2.5-20/~M) was coin- 
cubated with or without competitor peptides (200/zM) for the duration 
of the experiment.  Supernatants were harvested and assayed for IL-2 as 
described in Fig. 1 B. Data is representative of at least three experiments. 
EAE was induced as described in Table 1. For coimmunization, the com- 
petitor peptides (500 nmol) were mixed with Ac1-11 (25 nmol) in the 
same emulsion. Mice were scored daily as in Table 1. Data pooled from 
three separate experiments  is shown. 
* Chi-square  =  14.0, P  =  0.0002 when compared with Ac1-11 group. 
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of EAE, Ac5.6 had a substantial effect in reducing the inci- 
dence of EAE in  (PL/J  x  SJL/J)F1 mice (Table  2).  Since 
Ac3.6, which is a weak binder (Fig. 1 C and Fig. 2) did not 
inhibit the disease (Table 2), the data suggest that Ac5.6 in- 
hibits EAE by competing for the MHC class II binding of 
Ac1-11. Such inhibition  of EAE by competitive binding of 
Ac5.6 contrasts  markedly with disease prevention by Ac1- 
1114A] (3, 17). Unlike Ac1-1114A], Ac5.6 is non-crossreactive 
with Ac1-11. A recent report indicates that substituted pep- 
tide analogs can also act as antagonists for TCRs (18). The 
possibility that Ac5.6 may be inhibiting T  cell responses in 
vitro and EAE in vivo by acting as an antagonist for TCRs 
is not ruled out. 
Discussion 
We have shown in this report that  some Acl-ll  alanine- 
substituted peptide analogs, consisting mainly of alanines with 
just  a  few critical  native  amino  adds,  bind  to  Ac~uA/~, 
stimulate spedfic T cells in vitro and most importantly,  in- 
duce EAE. Previously, MHC class I mediated lysis has been 
inhibited by using competitor peptides substituted with ei- 
ther polyglycine or polyproline (19).  Binding of a polyala- 
nine peptide to HLA-DR1 has also been shown (20). How- 
ever, these studies did not examine induction ofT cell responses 
using these peptides. Our experiments demonstrate not only 
that MHC class II-restricted T cells can be stimulated in vitro, 
but also that EAE can be induced by a peptide that consists 
mainly of alanines.  This suggests that very few amino acids 
need to interact with MHC class II molecules and with TCRs 
to initiate specific responses in vivo resulting in autoimmune 
disease. Moreover, by defining key residues in Ac1-11, we have 
also  identified  a  peptide  that  binds  AotuAB u but  fails  to 
stimulate Ac1-ll-specific T  cells.  When used as a compet- 
itor,  this peptide inhibits  EAE in mice. 
Overall conformation of the peptide-MHC complex has 
been implicated as a structure recognized by TCRs (1, 7, 21). 
Our data strongly suggest that,  a peptide unrelated  to the 
immunizing  peptide can fulfill this requirement  as long as 
the  peptide contains  the  critical  MHC  and  TCR contact 
residues. Molecular mimicry has been suggested as a mecha- 
nism for autoimmunity (12,  13). Since only four or five na- 
tive residues in a peptide were able to induce EAE, it is con- 
ceivable that a pathogen (e.g., viral) with limited homology 
to self at few amino acid residues may trigger autoimmune 
disease. 
Finally,  we do not know whether a similar pattern of T 
cell stimulation in vitro and in vivo will be found in other 
antigen  systems.  Nevertheless,  in the absence of a detailed 
structure of class II MHC-peptide complexes, this report pro- 
vides a useful experimental system to study binding and T 
cell recognition of peptides, and to understand peptide con- 
formation and orientation in the binding  groove of MHC 
class  II molecules. 
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